HOXA11 and paraganglioma: For instance, HOXA11-AS predicted poor prognosis in patients with ACC, KICH, KIRC, LGG, and lung adenocarcinoma (LUAD), HOTTIP predicted poor prognosis in patients with ACC, KICH, KIRC, LGG, LUAD, and uveal melanoma (UVM), and HOTAIRM1 predicted poor prognosis in patients with ACC, GBM, KICH, KIRC, LGG, THYM, and UVM patients, but was found to be associated with a survival advantage for bladder urothelial carcinoma (BLCA) and pheochromocytoma/paraganglioma (PCPG).